May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego Hongchang QuSenior Director, Chemistry at Eli Lilly & Company
Profile
Dr. Qu is currently the Senior Director of the Peptide Therapeutic Group at Eli Lilly. Since he joined Lilly in 2013, he has led multiple preclinical peptide research projects and advanced them into clinical development to establish proof of concept. Prior to joining Eli Lilly, Dr. Qu was a Process Development Scientist for two years at the Polypeptide Laboratories. Dr. Qu holds a PhD degree in organic chemistry from the University of Arizona and had postdoctoral training at University of Pennsylvania.
Agenda Sessions
The Novel GIP, GLP-1, And Glucagon Triple Receptor Agonist LY3437943: From Discovery to Clinical Proof-of-Concept
, 11:15amView Session